-
Mashup Score: 2A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX - 3 day(s) ago
This case report illustrates the therapeutic opportunities offered through identification of homologous recombination repair deficiency in pancreatic cance
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
The prognostic value of the ESAS tool is unknown in gastroesophageal cancer. This study examined the association between the ESAS score and overall surviva
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Oncologist - 14 day(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Oncologist - 15 day(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
This study evaluated the association between insurer (commercial vs Medicaid) and the use of high-priced cancer treatments. Commercially insured and Medica
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Renaming Palliative Cancer Therapies: Call It What It Is - 24 day(s) ago
This commentary explores the language choices that oncology providers make when discussing cancer therapy goals.
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS - 30 day(s) ago
This report examines darolutamide tolerability from extended follow-up for both the double-blind and open-label treatment periods of the phase III ARAMIS t
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes - 1 month(s) ago
This is the largest study to date to evaluate the clinical impact of different timing and treatment patterns of first-line targeted therapy in patients with adv
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic - 1 month(s) ago
This study evaluated patient and disease characteristics, treatment, and prognosis of male breast cancer among patients registered with the Complex Oncological
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet-
Based on this study involving male #breastcancer patients, unfavorable features were common but did not affect prognosis. However, the prognosis of HR+ disease can be negatively affected by AI monotherapy without castration therapy. @CharlesUniPRG #bcsm https://t.co/Iw1JMVNLML https://t.co/QAwdZoxIGL
-
-
Mashup Score: 2A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR) - 1 month(s) ago
This article reports clinical trial results of a phase II trial assessing the efficacy of rucaparib in patients with high-risk biochemically recurrent nonmetast
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
'@DrGManji & colleagues present a case of a metastatic #pancsm to liver with somatic #BRCA2 mutation on somatic #NGS and extended survival (58+ m) compared to median #OS of <12m. They discuss importance of molecular tumor boards #GIonc https://t.co/S2b45CBnwB https://t.co/IdgZO00xxX